Abstract: Objective: To develop and preliminarily apply a management program for immune-related cutaneous adverse events in patients with lung cancer, and provide reference for related clinical practice. Methods: From February to May 2023, the first draft of the management plan was developed using literature research and interviews, guided by the modified dynamic symptom model. It was revised after the presentation at an expert meeting. Convenience sampling was employed in the study. Routine care was provided to the participants in the control group who were admitted in November 2023. A management program for immune-related cutaneous adverse events in lung cancer immunotherapy was provided to patients in the intervention group who were admitted in December 2023. Pre- and post-intervention comparisons were made between the two groups on skin reaction incidence, self-care abilities, health-promoting lifestyles, and psychological status. Results: The management program for immune-related cutaneous adverse events in lung cancer patients consisted of two parts including a preventive management program and a therapeutic management program. After the intervention, the incidence of immune-related cutaneous adverse events in lung cancer immunotherapy in the intervention group and control group was 31.0% and 48.3% respectively, with no statistically significant difference (P>0.05). While there were statistically significant differences in self-care ability between the two groups, with higher self-care ability scores in the intervention group (P<0.05). Conclusion: The management program is constructed based on evidence, combining patient needs and expert opinions, and has good scientific validity and reliability, providing a reference for healthcare professionals to carry out the prevention and management of immune-related cutaneous adverse events in lung cancer patients.

Key words: lung neoplasms; immune checkpoint inhibitors; cutaneous adverse events; symptom management; development of program